As of November 6, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of Bionano Genomics, Inc. The largest reported stake is Ayrton Capital LLC's, at 9.99%. 13 filings are on record since September 17, 2025 (Schedule 13G, November 13, 2025).
Sell to companies like Bionano Genomics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Orin Hirschman · Sole voting: 1,165,000 · Shared voting: 0 · Sole dispositive: 1,165,000 · Shared dispositive: 0 · SCHEDULE 13G, 2026-10-19
- · Reporting person: CVI Investments, Inc. · Sole voting: 0 · Shared voting: 1,307,135 · Sole dispositive: 0 · Shared dispositive: 1,307,135 · SCHEDULE 13G/A, 2026-08-14
- · Holder: Lind Global Fund III LP · Percent: 9.35% · SCHEDULE 13G/A
- · Holder: CVI Investments, Inc. · Percent: 9.9% · SCHEDULE 13G/A
- · Holder: Lind Global Fund III LP · Percent: 9.9% · SCHEDULE 13G/A
Bionano Genomics, Inc. has 13 Schedule 13D or 13G filings on record since 2025-09-17. 5 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Ayrton Capital LLC | 9.99% | 528,245 | SCHEDULE 13G, 2025-11-13 | 2025-09-30 |
| CVI Investments, Inc. | 9.9% | 1,307,135 | SCHEDULE 13G/A, 2026-08-14 | 2026-06-30 |
| 9.9% | 1,165,000 | SCHEDULE 13G, 2026-10-19 | 2026-09-30 | |
| Lind Global Fund III LP | 9.35% | 1,050,000 | SCHEDULE 13G/A, 2026-02-17 | 2025-12-31 |
| Lincoln Alternative Strategies LLC | 5.42% | 525,000 | SCHEDULE 13G, 2025-09-17 | 2025-09-17 |
| 4.99% | 98,944 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 | |
| 4.99% | 508,415 | SCHEDULE 13G, 2025-09-19 | 2025-09-16 |
Holding shares or following this stake? See who's behind Bionano Genomics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Bionano Genomics, Inc. and the records around it.
Bionano Genomics, Inc. elsewhere on the record
- Leadership changes Jun 2026
- Who owns it
Companies that share a holder
- Lind Global Fund III LP also filed stake reports on 11 other companies: Dare Bioscience, Inc. (Aug 2026), DEFSEC Technologies Inc. (Aug 2026), Enveric Biosciences, Inc. (Aug 2026)
- Iroquois Capital Management, LLC also filed stake reports on 13 other companies: 22nd Century Group (Aug 2026), XWELL, Inc. (Aug 2026), Clearmind Medicine Inc. (Aug 2026)
- Lincoln Alternative Strategies LLC also filed stake reports on 13 other companies: Celularity Inc (Feb 2026), Jaguar Health, Inc. (Feb 2026), Longeveron Inc. (Feb 2026)
Watch Bionano Genomics, Inc.
Get an email when Bionano Genomics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Bionano Genomics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Bionano Genomics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Bionano Genomics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| CVI Investments, Inc. | 0 | 1,307,135 | 0 | 1,307,135 | SCHEDULE 13G/A, 2026-08-14 |
| Heights Capital Management, Inc. | 0 | 1,307,135 | 0 | 1,307,135 | SCHEDULE 13G/A, 2026-08-14 |
| Orin Hirschman | 1,165,000 | 0 | 1,165,000 | 0 | SCHEDULE 13G, 2026-10-19 |
| AIGH Capital Management LLC | 1,165,000 | 0 | 1,165,000 | 0 | SCHEDULE 13G, 2026-10-19 |
The latest filing identifies Bionano Genomics, Inc. by CUSIP 09075F404 and gives its principal executive office as 9540 Towne Centre Drive, Suite 100, San Diego, CA 92121 (SCHEDULE 13G, 2026-10-19).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-09-17 | Lincoln Alternative Strategies LLC | 5.42% | SCHEDULE 13G |
| 2025-09-18 | Richard Abbe | 5.4% | SCHEDULE 13G |
| 2025-09-19 | Mitchell P. Kopin | 4.99% | SCHEDULE 13G |
| 2025-09-22 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G |
| 2025-09-24 | Lind Global Fund III LP | 9.9% | SCHEDULE 13G |
| 2025-11-13 | Ayrton Capital LLC | 9.99% | SCHEDULE 13G |
| 2025-11-14 | Lind Global Fund III LP | 9.9% | SCHEDULE 13G/A |
| 2025-11-14 | Iroquois Capital Management, LLC | 4.99% | SCHEDULE 13G/A |
| 2025-11-14 | Richard Abbe | 4.99% | SCHEDULE 13G/A |
| 2026-02-17 | Lind Global Fund III LP | 9.35% | SCHEDULE 13G/A |
| 2026-02-17 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-08-14 | CVI Investments, Inc. | 9.9% | SCHEDULE 13G/A |
| 2026-10-19 | Orin Hirschman | 9.9% | SCHEDULE 13G |
Questions about who owns Bionano Genomics, Inc.
Who owns Bionano Genomics, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Bionano Genomics, Inc.: Ayrton Capital LLC (9.99%, Schedule 13G, filed 2025-11-13), CVI Investments, Inc. (9.9%, Schedule 13G/A, filed 2026-08-14), Orin Hirschman (9.9%, Schedule 13G, filed 2026-10-19), Lind Global Fund III LP (9.35%, Schedule 13G/A, filed 2026-02-17) and Lincoln Alternative Strategies LLC (5.42%, Schedule 13G, filed 2025-09-17).
Who are the largest shareholders of Bionano Genomics, Inc.?
By the share each holder's latest filing reports, the largest holders of Bionano Genomics, Inc. on this page are Ayrton Capital LLC (9.99%), CVI Investments, Inc. (9.9%) and Orin Hirschman (9.9%).
When did Ayrton Capital LLC buy into Bionano Genomics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ayrton Capital LLC on this page is the Schedule 13G, filed 2025-11-13, reporting 9.99%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 13 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Bionano Genomics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 5, 2026 | Leadership change filing (Form 8-K, Item 5.02) | — | Leadership changes | Source |
| May 6, 2026 | Leadership change: R. Erik Holmlin departs, and 1 more | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Bionano Genomics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.